Envestnet Asset Management’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-64,185
| Closed | -$259K | – | 4447 |
|
|
2025
Q1 | $259K | Sell |
64,185
-2,650
| -4% | -$8.83K | ﹤0.01% | 4003 |
|
|
2024
Q4 | $214K | Sell |
66,835
-16,797
| -20% | -$56.9K | ﹤0.01% | 4067 |
|
|
2024
Q3 | $187K | Buy |
83,632
+277
| +0.3% | +$639 | ﹤0.01% | 4030 |
|
|
2024
Q2 | $179K | Buy |
83,355
+6,713
| +9% | +$12K | ﹤0.01% | 3957 |
|
|
2024
Q1 | $157K | Buy |
76,642
+33,462
| +77% | +$66.8K | ﹤0.01% | 3995 |
|
|
2023
Q4 | $98.9K | Sell |
43,180
-5,162
| -11% | -$11.2K | ﹤0.01% | 3942 |
|
|
2023
Q3 | $82.2K | Buy |
48,342
+3,025
| +7% | +$6.87K | ﹤0.01% | 3896 |
|
|
2023
Q2 | $112K | Buy |
45,317
+11,368
| +33% | +$31.1K | ﹤0.01% | 3820 |
|
|
2023
Q1 | $76.4K | Buy |
33,949
+6,144
| +22% | +$30.8K | ﹤0.01% | 3822 |
|
|
2022
Q4 | $142K | Buy |
27,805
+18,221
| +190% | +$131K | ﹤0.01% | 3745 |
|
|
2022
Q3 | $100K | Buy |
9,584
+2,458
| +34% | +$29.3K | ﹤0.01% | 3737 |
|
|
2022
Q2 | $73K | Sell |
7,126
-654
| -8% | -$8.57K | ﹤0.01% | 3786 |
|
|
2022
Q1 | $138K | Buy |
7,780
+1,095
| +16% | +$23.5K | ﹤0.01% | 3766 |
|
|
2021
Q4 | $208K | Buy |
6,685
+718
| +12% | +$23.8K | ﹤0.01% | 3638 |
|
|
2021
Q3 | $197K | Buy |
5,967
+4,339
| +267% | +$128K | ﹤0.01% | 3506 |
|
|
2021
Q2 | $48K | Buy |
1,628
+427
| +36% | +$11.8K | ﹤0.01% | 3604 |
|
|
2021
Q1 | $38K | Buy |
1,201
+17
| +1% | +$570 | ﹤0.01% | 3461 |
|
|
2020
Q4 | $31K | Buy |
+1,184
| New | +$30K | ﹤0.01% | 3246 |
|
Envestnet Asset Management's CKPT Position: Q2 2025 in Review
Envestnet Asset Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 64,185 shares — an estimated $259K sold.
Envestnet Asset Management first reported a position in CKPT in Q4 2020 and held it in 18 quarters. The position peaked at $259K in Q1 2025. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Envestnet Asset Management reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Envestnet Asset Management sold 64,185 Checkpoint Therapeutics shares in Q2 2025, an estimated $259K.
- Envestnet Asset Management first reported a position in Checkpoint Therapeutics in Q4 2020 and held it in 18 quarters.
- Envestnet Asset Management's Checkpoint Therapeutics position peaked at $259K in Q1 2025.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.